Canopy Growth's Quarterly Beat Collides With an Accounting Cloud
Published on 08/10/2026 at 16:11 | Redaktion boerse-global.de
The arithmetic of Canopy Growth's turnaround is finally moving in the right direction. The Canadian cannabis producer trimmed its net loss to 14.6 million Canadian dollars in the first quarter of fiscal 2027, a 68 percent improvement from the 44.9 million dollar deficit recorded a year earlier. Revenue rose 13 percent to 81.2 million Canadian dollars, and the per-share loss of 0.03 dollars landed comfortably ahead of the 0.06 dollar consensus that analysts had penciled in.
Yet the market's response has been muted, and for good reason. Buried in the company's definitive proxy statement filed alongside the earnings release is a disclosure that complicates the recovery narrative: the audited financial statements for fiscal 2024 and 2025 can no longer be relied upon. The culprit is a technical, non-cash error in how share-settled warrants were classified. Canopy Growth has since appointed MNP as its new independent auditor, replacing PKF O'Connor Davies.
The stock, which closed Friday at 0.8352 euros in German trading, has shed 19.85 percent since the start of the year and sits 58.20 percent below its December high. In Toronto, shares changed hands Monday at 1.33 Canadian dollars, while the Nasdaq listing traded at 0.98 US dollars. The German listing currently sits around 0.8376 euros, roughly 12 percent beneath its 200-day moving average of 0.9504 euros, though the 11.68 percent rebound from the March 30 52-week low suggests some stabilization after the slide from December's 2.00 euro peak.
The EBITDA Question That Matters
For investors, the investment thesis has narrowed to a single metric: whether management can deliver on its promise of positive adjusted EBITDA in fiscal 2027. The company is banking on 10 million Canadian dollars in synergies from the MTL Cannabis integration, expected to materialize within 18 months. Early signs are encouraging — the adjusted gross margin jumped to 31 percent in the quarter from 25 percent a year earlier, and the adjusted EBITDA loss shrank 59 percent to 3.2 million Canadian dollars.
Segment performance adds texture to the picture. Canadian medical cannabis sales grew 22 percent to 25.8 million dollars, while the Storz & Bickel vaporizer division advanced 6 percent to 16.1 million dollars. International markets contributed a 10 percent increase. Zacks Investment Research separately noted that the reported loss per share of 0.05 Canadian dollars undercut the 0.10 dollar consensus by half, a discrepancy from the 0.03 dollar figure cited elsewhere that reflects differences in calculation methodology.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Governance Shadows Linger
The accounting restatement is not the only governance concern weighing on the stock. A management cease trade order from the Ontario Securities Commission remains in effect against CEO Luc Mongeau and CFO Thomas Stewart, barring both from trading company shares until corrected financials are filed. The company also faces the familiar burden of past legal entanglements: an Ontario court confirmed a settlement with KPMG on August 5 in a class action over allegedly misleading audit reports for the fiscal year ending March 31, 2022, with terms remaining confidential.
The proposed share consolidation — between 1-for-5 and 1-for-15 — that shareholders will vote on at the September 25 annual meeting adds another layer of uncertainty. Such measures often signal persistent share price pressure, and with annualized volatility at 47.58 percent, near-term turbulence seems plausible regardless of the vote's outcome.
Mixed Signals From the Institutional Sidelines
The analyst community remains divided. Wall Street Zen upgraded the stock from "Sell" to "Hold" on Friday, a cautious but notable shift after months of negative ratings. Weiss Ratings, the automated screening house, moved its assessment from "sell (e+)" to "sell (d-)" in late July — still firmly negative, but marginally less so.
Institutional activity tells a more nuanced story. Lazard Asset Management built a new position of 1,807,986 shares in early August, while Tidal Investments increased its stake by 31.5 percent to roughly 5 million shares. More significantly, Constellation Brands has held its ground: as of late July, the beverage giant maintained approximately 26.26 million convertible shares, representing about 5.8 percent of the company on a converted basis against 423 million outstanding common shares. A strategic investor of that scale staying put through accounting restatements and trading bans offers at least a tentative vote of confidence.
What Comes Next
Two upcoming events will provide the next concrete data points. CEO Luc Mongeau is scheduled to appear at the Canaccord Genuity Growth Conference on Tuesday, and the annual meeting on September 25 will decide the fate of the share consolidation. Management continues to frame US Schedule III reclassification as a positive industry development, though the company itself identifies Europe and MTL Cannabis as the near-term growth drivers.
The core tension is straightforward: Canopy Growth is demonstrably improving its operations, but it must simultaneously rehabilitate the credibility of its own financial reporting. The market's skepticism — reflected in a share price that has yet to reclaim even half of its December value — suggests investors are waiting for the corrected statements before fully underwriting the recovery story. The path to positive adjusted EBITDA remains realistic if Canadian growth holds, Storz & Bickel maintains momentum, and the MTL synergies arrive as promised. Whether that operational progress can outrun the accounting legacy is the question that will define the coming quarters.
Ad
Canopy Growth Stock: New Analysis - 10 August
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
